Skip to main content
SpringerLink
Log in

Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support

  • Original Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

In a population-based study, the Nordic Myeloma Study Group found a survival advantage for high-dose melphalan with autologous blood stem-cell support compared to conventional chemotherapy in myeloma patients under 60 yr of age (risk ratio: 1.62; confidence interval [CI] 1.22–2.15; p=0.001). A study of health-related quality of life (HRQoL) was integrated in the trial, using the EORTC QLQ-C30 questionnaire. Of the 274 patients receiving intensive therapy 221 (81%) were compared to 113 (94%) of 120 patients receiving conventional melphalan-prednisone treatment.

Prior to treatment, there were no statistically significant differences in any HRQoL score between the two groups. One month after the start of induction chemotherapy, the patients on intensive treatment had more sleep disturbance than the control patients. At 6 mo, corresponding to a mean of 52 d after high-dose melphalan, the patients on intensive treatment had moderately lower scores for global QoL and role and social functioning and there was also a significantly higher score for appetite loss. At 12 and 24 mo, the HRQoL was similar to that of the control patients. At 36 mo, there was a trend toward less fatigue, pain, nausea, and appetite loss in the intensive-treatment group. Thus, the 18 mo of prolonged survival seem to be associated with a good health-related quality of life. Despite the moderate HRQoL reduction associated with the early intensive chemotherapy phase, this treatment modality must be regarded as an important step forward in the care of multiple myeloma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wisloff, F., et al. (1996). Measurement of health-related quality of life in multiple myeloma. Br. J. Haematol. 92:604–613.

    Article  PubMed  CAS  Google Scholar 

  2. Hjorth, M., et al. (1999). Survival in conventionally treated younger (< 60 years) multiple myeloma patients: no improvement during two decades. Eur. J. Haematol. 62: 271–277.

    Article  PubMed  CAS  Google Scholar 

  3. The Myeloma Trialists’ Collaborative Group. (1998). Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J. Clin. Oncol. 16:3832–3842.

    Google Scholar 

  4. Attal, M., et al. (1996). A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N. Engl. J. Med. 335:91–97.

    Article  PubMed  CAS  Google Scholar 

  5. Barlogie, B., et al. (1997). Superiority of trandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89:789–793.

    PubMed  CAS  Google Scholar 

  6. Lenhoff, S., et al. (2000). Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood 95:7–11.

    PubMed  CAS  Google Scholar 

  7. Hjorth, M., et al. (1996). Interferon-α 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. Ann. Intern. Med. 124:212–222.

    CAS  Google Scholar 

  8. Wisløff, F., Hjorth M., Kaasa, S. and Westin, J. (1996). Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan- prednisone + α-interferon. Br. J. Haematol. 94:324–331.

    Article  PubMed  Google Scholar 

  9. Aaronson, N.K., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ C-30: a quality of life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 85:365–376.

    Article  PubMed  CAS  Google Scholar 

  10. Kaasa, S., et al. (1995). The EORTC Core Quality of Life Questionnaire (QLQ C-30): validity and reliability when analyzed with patients treated with palliative radiotherapy. Eur. J. Cancer 31A:2260–2263.

    Article  PubMed  CAS  Google Scholar 

  11. Hjermstad, M.J., Fossa, S.D., Bjordal, K. and Kaasa, S. (1996). Test/retest study of the European Organization for Research and Treatment of Cancer core quality of life questionnaire. J. Clin. Oncol. 13:1249–1254.

    Google Scholar 

  12. Fayers, P., Aaronson, N., Bjordal, K. and Sullivan, M. (1995). EORTC QLQ C-30 Scoring Manual, EORTC Study Group on Quality of Life, Brussels.

    Google Scholar 

  13. King, M.T. (1996). The interpretation of scores from the EORTC quality of life questionnaires QIQ-C30. Qual. Life Res. 5:555–567.

    Article  PubMed  CAS  Google Scholar 

  14. Osoba, D., Rodrigues, G., Myles, J., Zee, B. and Pater, J. (1998). Interpreting the significance of changes in health-related quality-of-life scores. J. Clin. Oncol. 16:139–144.

    PubMed  CAS  Google Scholar 

  15. Altman, D.G. (1991). Practical Statistics for Medical Research. Clinical Trials: Sample Size, pp. 455–460, Chapman & Hall, Cornwall, UK.

    Google Scholar 

  16. Henon, P., Donatini, B., Eisenmann, J.C., Becker, M. and Beck-Wirth, G. (1995). Comparative survival, quality of life and cost-effectiveness of intensive therapy with autologous blood cell transplantation or conventional chemotherapy in multiple myeloma. Bone Marrow Transplant 16:19–25.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rikshospitalet, Ullevål University Hospital, Oslo, Norway

    L. Brinch

  2. Akademiska Hospital, Uppsala, Sweden

    K. Carlson

  3. Tromsø University Hospital, Tromosø, Norway

    I. M. Dahl

  4. Rigshospitalet, København, Denmark

    P. Gimsing

  5. Kobenhavn University Hospital, Herlev, Denmark

    E. Hippe & L. M. Knudsen

  6. Lidkøping Hospital, Lidkøping, Sweden

    M. Hjorth

  7. Trondheim University Hospital, Trondheim, Norway

    J. Lamvik

  8. Lund University Hospital, Lund, Sweden

    S. Lenhoff & J. Westin

  9. Norrland University Hospital, Umeå, Sweden

    E. Løfvenberg

  10. Haukeland Hospital, Bergen, Norway

    I. Nesthus

  11. Arhus University Hospital, Århus C., Denmark

    J. Lanng Nielsen

  12. Malmø University Hospital, Malmø, Sweden

    I. Turesson

  13. Department of Hematology, Ullevål University Hospital, 0407, Olso, Norway

    N. Gulbrandsen & F. Wisløff

Authors
  1. N. Gulbrandsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Wisløff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Brinch
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Carlson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. M. Dahl
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. Gimsing
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E. Hippe
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Hjorth
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L. M. Knudsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J. Lamvik
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S. Lenhoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. E. Løfvenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. I. Nesthus
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. J. Lanng Nielsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. I. Turesson
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. J. Westin
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

The Nordic Myeloma Study Group

Corresponding author

Correspondence to N. Gulbrandsen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gulbrandsen, N., Wisløff, F., Brinch, L. et al. Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support. Med Oncol 18, 65–77 (2001). https://doi.org/10.1385/MO:18:1:65

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/MO:18:1:65

Key Words

Search

Navigation